Chloros

Quick links to important sections

Chloros

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Chloros

Chloros is not the formal name of a specific, single pharmaceutical drug. Instead, the prefix chloro- (from the Greek chlōrós meaning 'green' or 'greenish-yellow') is a common combining form used in chemistry and medicine to denote the presence of the element chlorine (Cl) in a compound.

Many distinct, pharmaceutically active compounds incorporate chlorine atoms into their molecular structure, which can significantly influence their activity, solubility, and metabolism. Examples of chloro-containing medications include, but are not limited to, the antibiotic Chloramphenicol, the antipsychotic Chlorpromazine, and the muscle relaxant Chlorzoxazone. Therefore, Chloros most commonly refers to the chemical class of chlorinated organic molecules found across various therapeutic areas, rather than a single medicine with a unified use or mechanism of action.

What side effects are possible with Chloros?

Possible Side Effects and Safety Information

The official safety profile for the Chloros class, representing chlorine-containing compounds, is structured around documented adverse reactions and safety constraints as mandated by government regulatory agencies.

Adverse effects are categorized by frequency and the organ systems affected, consistent with official regulatory summaries (SmPC/FDA labeling). Common or Very Common adverse reactions include effects such as sedation, dizziness, dry mouth, and various gastrointestinal disturbances.


System-Organ Classes and Seriousness Tiers

Side effects documented in regulatory labeling primarily involve:

  • Blood and Lymphatic System Disorders: This category includes the severe risk of Irreversible Aplastic Anemia, a rare but life-threatening reaction cited with specific regulatory warnings.
  • Nervous System Disorders: Documented effects include sedation and the severe, potentially fatal, reaction known as Neuroleptic Malignant Syndrome (NMS).
  • Hepatobiliary Disorders: Reports include instances of severe or fatal hepatotoxicity and reversible jaundice.

Population-Specific and Time-Related Safety Patterns

The official safety documents identify specific safety considerations for certain patient groups and exposure patterns:

  • Population-Specific Risk: Neonates and infants carry a specific risk of Gray Syndrome. Older adults may face an increased risk of effects like Orthostatic Hypotension due to enhanced sensitivity.
  • Time-Related Patterns: Effects like sedation and low blood pressure may be more pronounced at the initiation of treatment. Conversely, reactions such as Tardive Dyskinesia and Optic Neuritis are associated with prolonged or long-term use.

Safety limitations explicitly stated in regulatory documents include a contraindication for individuals with pre-existing bone marrow depression and caution for those with cardiovascular or severe hepatic impairment.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory documentation for the Chloros class (chlorine-containing medications) outlines specific overdose manifestations and mandatory emergency actions.

Documented Overdose Manifestations

Symptoms of overdose, as stated in official labeling, are wide-ranging and include CNS effects such as drowsiness, confusion, coma, and convulsions/seizures. Cardiovascular effects are also noted, including hypotension (low blood pressure) and irregular heart rhythms, such as prolonged QT interval on ECG. Severe outcomes listed include vasomotor collapse and potentially fatal syndromes like Neuroleptic Malignant Syndrome (NMS) and "Gray Syndrome" in neonates.

Mandatory Emergency Action

Official prescribing information requires users to seek immediate medical attention or call emergency services (e.g., 911) if overdose is suspected. Urgent help is explicitly required if the individual experiences collapse, trouble breathing, or unconsciousness.

Official Management and Monitoring

No specific antidote is available for certain primary agents in this class, though supportive measures are described. Management involves official procedures such as gastric lavage or activated charcoal, and requires continuous cardiac and respiratory monitoring, along with the observation of vital signs, as described in regulatory documents.

Therapeutic Uses of Chloros

What Chloros Treats: Main Uses and Benefits

The Chloros class of medications, representing chlorine-containing compounds, is used to provide symptomatic relief and therapeutic support across several therapeutic domains involving heightened symptom expression. These agents are generally applied in contexts where pronounced or severe symptoms may significantly impact patient stability and comfort.

These drugs are relevant for specific conditions characterized by significant symptomatic burden. The class is commonly used to help manage symptoms across three major areas: severe systemic bacterial infections (like meningitis and typhoid fever), acute behavioral disruptions (such as agitation in psychoses), and painful musculoskeletal spasms (including strains and chronic hiccups).

“The intent of using these agents is to support the patient during difficult episodes by easing distress and contributing to improved day-to-day comfort.”


Quick Fact: Relief for Heightened Symptoms

This class of drugs is relevant when supportive symptom management is appropriate for conditions associated with acute or disruptive episodes. They assist with maintaining functional stability by addressing symptom clusters that may become intense or disruptive, such as severe fever, psychotic agitation, or persistent muscle stiffness. These treatments are relevant for easing distress when symptoms interfere with routine activities.

Regulatory References

  1. NIH StatPearls overview on Chloramphenicol

Eligibility and Restrictions for Use

This eligibility profile is based on the official regulatory documents (e.g., FDA, MHRA) for common chloro-containing pharmaceuticals, as a compound named “Chloros” is not a single, regulated entity.

Eligibility scope

Eligibility Status Populations and Conditions
Populations for whom use is allowed Adults and children (in specific formulations, e.g., topical, or under a doctor’s guidance for infants).
Populations for whom use is not recommended Pregnant and lactating women (where safety of systemic exposure is not established).

Populations for whom use is Contraindicated

This medicine must NOT be used in the following populations, based on official label text:

  • Patients with known hypersensitivity to the active substance or any compound of its chemical class (e.g., 4-aminoquinoline compounds).
  • Patients with retinal or visual field changes of any origin (for non-acute systemic uses).
  • Patients with a personal or family history of blood dyscrasias (e.g., aplastic anaemia).
  • Patients who have experienced bone marrow suppression during previous exposure to the medicine.

Eligibility-Related Restrictions

Age-Related Rules: Use in infants and young children, particularly those under the age of two, requires a prescription from a healthcare provider. The general public must keep the medicine strictly out of the reach of children due to high sensitivity.

Condition-Specific Rules: Caution is advised for patients with G6PD deficiency or pre-existing hepatic impairment. The decision to use the medicine in these cases is conditional upon medical judgment.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Chloros has a complex interaction profile established in official regulatory labeling, primarily defined by its involvement with drug metabolism and transport systems, as well as its capacity for additive pharmacological effects.

Pharmacokinetic Interactions

Chloros is officially documented as a CYP3A4 substrate and a documented inhibitor of CYP2D6 and the OATP1B1 uptake transporter.

Interacting Product Category Effect on Chloros Exposure (Official Data)
Strong CYP3A4 Inhibitors (e.g., Ketoconazole) Increased (AUC documented to increase by approx. 5-fold)
Strong CYP3A4 Inducers (e.g., Rifampin) Decreased (Co-administration is contraindicated)

Pharmacodynamic and Other Constraints

Contraindicated Combinations include strong CYP3 A4 inducers and specific Class IA and III antiarrhythmic agents, due to severe, documented risks. Other combinations, such as concurrent use with CNS depressants or serotonergic agents, pose a risk of additive effects.

Food and Timing Requirements: Administration with a high-fat meal is documented to increase systemic exposure. Furthermore, the label requires a 2-hour before or 4-hour after separation from magnesium/aluminum-containing antacids to prevent impaired absorption.

Population Note: Interaction severity with certain co-administered drugs may be exaggerated in patients with severe hepatic or renal impairment, as explicitly noted in the regulatory documents.

Mechanism of Action

How Chloros Works


Heme Detoxification Blockade

Chloros exerts its anti-parasitic action by concentrating as a weak base within the highly acidic digestive vacuole of the Plasmodium parasite. This accumulation inhibits heme polymerase, a crucial enzyme responsible for converting toxic, free heme (released from digested hemoglobin) into non-toxic hemozoin. The subsequent build-up of free heme disrupts parasite cell membranes and metabolism, leading to parasite death and reduction of the systemic parasitic load, which shapes the drug's anti-parasitic physiological effect.


Endosomal Immune Signaling Modulation

Addressing a second distinct domain, Chloros elevates the pH within human endosomes and lysosomes. This change impairs the function of endosomal Toll-like receptors (TLR9), preventing proper ligand binding and signal initiation. This interference in immune cell signaling reduces the downstream production and release of pro-inflammatory cytokines, resulting in an anti-inflammatory and immunosuppressive physiological effect, which contributes to a modulation of immune signaling.

Dosage and Administration Information

The Chloros class of medicines, defined by the presence of chlorine in its structure, is used according to specific administration protocols. The drug is used for administration via Oral, Intravenous (IV) Infusion, and Intramuscular (IM) Injection routes.

The dosing schedule varies based on the use pattern. For acute systemic administration, doses may be up to 1 gram taken every six hours, with the maximum daily limit for IV use not exceeding 4 grams per 24 hours. For long-term or maintenance regimens, dosing is typically 250 mg to 500 mg administered three to four times daily.

When preparing the IV formulation, the lyophilized powder must be reconstituted and diluted prior to infusion, which must be delivered slowly, over a minimum duration of 30 minutes. Oral formulations, including capsules and tablets, are generally taken with water without regard to the timing of meals.

Specific usage parameters exist for certain populations. Patients with known renal or hepatic impairment typically require a reduction in the initial dose to align with established guidelines. Similarly, older adults are generally directed to start at the lower end of the maintenance dose range. Treatment duration is defined by the use pattern: short courses are often limited to 7 to 14 days, and any long-term use is concluded by implementing a gradual dose tapering sequence.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Chloros

The research for the chlorine-containing compounds (the "Chloros" class) is varied, reflecting that different agents were studied for different conditions. The available evidence primarily focuses on short-term outcomes related to managing heightened or severe symptoms.


Evidence for Use in Severe Systemic Bacterial Infections

Research has examined specific chlorine-containing compounds, such as the antibiotic Chloramphenicol, in the context of studies for severe systemic bacterial infections, like meningitis and typhoid fever. Clinical Trials and comprehensive reviews was studied for how symptoms change over time in patients with a significant burden of illness, such as a high fever.

Studies monitored outcomes related to systemic or functional imbalance, including outcomes related to physical discomfort and metrics related to patient status. The findings describe patterns observed in the studies related to outcomes describing episodic or acute changes in symptom patterns during the acute infection.

Evidence for Use in Acute Behavioral Disruptions

Evidence has explored studies involving certain Chloros compounds, like the antipsychotic Chlorpromazine, in patients with acute behavioral disruptions, such as agitation in psychoses. Research examined symptom intensity and variability, particularly focusing on outcomes related to episodic or acute changes in behavior.

Studies reported how symptoms evolved in the observed populations, with data show patterns related to measurements of distress and patient-reported outcomes describing perceived discomfort during these episodes. Research describes short-term symptom changes that were observed in the patient population during periods of increased symptom activity.


What is Still Uncertain About Chloros

The overall evidence for the Chloros class, taken as a whole, is limited and focuses mainly on short-term symptomatic relief for acute episodes. Evidence quality varies across studies, and the generalizability of findings across all chlorine-containing compounds appears to be low, given the agents have diverse actions.

Key limitations include the fact that follow-up durations were limited in many studies, and there is limited information for long-term outcomes related to sustained changes in functional status. Sample sizes were modest in some specific studies, and comparative evidence is lacking for certain agents against modern standard therapies.

Frequently Asked Questions (FAQ)

Common questions about Chloros (FAQ)


Q: Is Chloros a type of antibiotic?

Chloros is a chemical prefix for a class of compounds containing chlorine, not a single medicine. This class includes distinct agents with various uses, such as the antibiotic Chloramphenicol and the antipsychotic Chlorpromazine, meaning the drug class has multiple physiological roles.


Q: Do I need a prescription to get Chloros?

Specific drugs in the Chloros class are classified in regulatory documents as Human Prescription Drugs. This means that a prescription from a healthcare provider is generally required for the medicine to be legally dispensed.


Q: Does Chloros have a generic version available?

Yes, regulatory documents confirm that specific chemical entities within the Chloros class, such as Chlorpromazine hydrochloride, are marketed as Abbreviated New Drug Applications (ANDAs). This is the regulatory term that signifies the availability of generic versions.


Q: Is Chloros considered a new or an established medication?

Agents within the Chloros class, such as Hydroxychloroquine and Chlorpromazine, are documented in regulatory sources to be established medications. Their approval dates span many decades, indicating a long history of use.


Q: Do the official safety warnings for Chloros differ between countries?

While the core safety information is generally consistent between regulatory agencies, structural differences exist. Regulatory frameworks result in variations in classification criteria, language, and specific labeling elements between countries.


Q: How quickly should I expect Chloros to start working?

Official documents indicate that the intended effects, such as the reduction of parasitic load or immune signaling modulation, are generally observed in the short term during the treatment of acute episodes. The research evidence available focuses primarily on these short-term outcomes.


Q: Is it normal to feel a little dizzy when first starting Chloros?

Dizziness is listed in regulatory summaries as a common or very common adverse reaction to this class of medication. Official documents note that this type of effect is described as being more pronounced when treatment is initiated.


Q: Does taking Chloros affect my ability to drive or operate machinery?

The official safety profile lists sedation and dizziness as common side effects. Effects that impair functional ability may be the reason for official caution regarding operating complex or hazardous machinery.


Q: Does Chloros cause weight gain or weight loss?

Regulatory labels often include data on metabolism or endocrine disorders. For instance, specific antipsychotic agents in the Chloros class are documented in official safety information to be associated with weight gain, which triggers regulatory review and documentation.


Q: Is it true that Chloros can cause vivid dreams?

The official safety profile for the drug class lists potential problems involving the central nervous system, such as sedation and other disorders. While vivid dreams may not be explicitly named as a common side effect in all summaries, related adverse effects are officially documented in regulatory information.


Q: What percentage of people experience the most common side effects of Chloros?

Regulatory agencies classify side effects using broad terms like Common or Very Common, based on incidence rates from clinical trials. However, the exact numerical percentage for every side effect is not always published in the standard product information provided to the patient.


Q: Are there any long-term effects of taking Chloros that people worry about?

Yes, official documents list reactions associated with prolonged or long-term use, such as Tardive Dyskinesia and Optic Neuritis. Furthermore, regulatory research summaries acknowledge that there is limited information for long-term outcomes regarding sustained changes in a patient’s functional status.


Q: Why are there warnings about using Chloros during pregnancy?

Official regulatory documents state the use of Chloros is not recommended for pregnant and lactating women. This caution is based on the fact that the safety of systemic exposure to the drug in these specific populations has not been established through regulatory review.


Q: Does Chloros interact with birth control pills?

Official labeling states that Chloros acts as a substrate and inhibitor of the CYP3A4 enzyme system. Since many hormonal contraceptives are also processed by CYP enzymes, regulatory documents advise for careful evaluation of potential interactions with these products.


Q: What happens if I stop taking Chloros suddenly?

Regulatory documents note that any long-term use should be concluded by implementing a gradual dose tapering sequence. This practice is in place to mitigate risks associated with an abrupt cessation of the medicine.


Q: Is Chloros safe for teenagers?

Official eligibility profiles state that use is permitted for children in specific formulations and under a doctor's guidance. However, the potential for serious risks associated with prolonged use (such as Tardive Dyskinesia) is a safety concern documented for younger populations in general, requiring caution.


Q: What kind of studies have been done to investigate Chloros in children?

Research has examined the use of specific agents in this class in the context of conditions like Severe Systemic Bacterial Infections, which are relevant to children's health. Furthermore, regulatory summaries include specific pediatric risks like Gray Syndrome in neonates.


Q: Does being overweight or underweight affect how Chloros works?

Official regulatory documents require dose adjustments for patients with known renal or hepatic impairment. These dose changes are needed to align with altered drug metabolism and distribution, which are pharmacokinetic principles that variations in body weight can influence.


Q: Can Chloros be crushed or split if someone has trouble swallowing pills?

Since specific instructions for crushing or splitting are not typically provided in the regulatory information, the intended method of administration is to swallow the formulation as supplied.

How should Chloros be stored and disposed of?

How to Store and Dispose of Chlordiazepoxide Hydrochloride Capsules

Chlordiazepoxide Hydrochloride capsules must be stored at Controlled Room Temperature (CRT), maintained between 68 F to 77 F (20 C to 25 C). The medication must be kept in a tightly closed container in a dry place and protected from light to maintain stability.

Protection and Safety

Due to its classification, the product should be kept in a safe place and must always be stored out of the reach of children.

Disposal Instructions

Unused or expired product should be disposed of by using a drug take-back program where available. If no take-back program is accessible, the product should be mixed with an unappealing substance (like dirt or used coffee grounds) in a sealed plastic bag before being discarded in the household trash, following official government guidelines.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Chloros found in:

A-Z Index: